Isorhynchophylline (20-40 mg/kg, i.g., daily, 8 weeks) ameliorates D-galactose (HY-N0210)-induced learning and memory deficits in mice, at least in part, by enhancing the antioxidant status and anti-inflammatory effects of brain tissue through inhibition of NFκB signaling[9].
Isorhynchophylline (50 μM, the first day of every week from the 5th to the 8th week after surgery) alleviates osteoarthritis in rat osteoarthritis models, with decreasing OARSI score and the reduction of joint space[7].
Isorhynchophylline (10-40 mg/kg, i.g., 7 days) exerts antidepressant-like effects in mice at least in part by inhibiting monoamine oxidase[10].
Isorhynchophylline (20-40 mg/kg, i.g., daily, 8 weeks) alleviates learning and memory impairments induced by aluminum chloride in mice[11].
Isorhynchophylline (20 mg/kg, i.p., 14 or 42 days) alleviates silicon-dioxide-induced lung injury in mice, with reducing inflammatory responses and fibrosis[12].
| Animal Model: | D-galactose-induced cognitive deficits (Ten-week-old male ICR mice received a daily subcutaneous injection of D-gal at a dose of 100 mg/kg for 8 weeks)[9] |
| Dosage: | 20, 40 mg/kg |
| Administration: | Given intragastrically (i.g.), daily, 8 weeks |
| Result: | Shortened the mean latency to find the platform at the 4th day (20 mg/kg).
Led to a significant increase in the number of target crossings (40 mg/kg).
Attenuated oxidative stress (enhanced the level of GSH, attenuated MDA).
Decreased the production of NO and the mRNA expression of iNOS in the brain (40 mg/kg).
Decreased the production of PGE2 and the mRNA expression of COX-2 (40 mg/kg).
Suppressed the protein level of p-IκBα (40 mg/kg).
|
